Lars F Berglund

List of Publications by Year
in descending order

160 papers	10,628 citations	53939 47 h-index	37326 100 g-index
163 all docs	163 docs citations	163 times ranked	11860 citing authors

#	Article	IF	Citations
1	Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, ATV0000000000000147.	1.1	207
2	Entrepreneurship and innovation in clinical and translational science. Journal of Clinical and Translational Science, 2022, 6, e15.	0.3	2
3	Non-genetic influences on lipoprotein(a) concentrations. Atherosclerosis, 2022, 349, 53-62.	0.4	36
4	Building an institutional K awardee program at UC Davis through utilization of CTSA resources. Journal of Clinical and Translational Science, 2021, 5, e171.	0.3	1
5	Lp(a)â€Associated Oxidized Phospholipids in Healthy Black and White Participants in Relation to apo(a) Size, Age, and Family Structure. Journal of the American Heart Association, 2021, 10, e020158.	1.6	8
6	Lp(a) and SARSâ€CoVâ€2: A conspiracy of two mysteries. Journal of Internal Medicine, 2021, , .	2.7	1
7	Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)?. Nutrients, 2020, 12, 2024.	1.7	40
8	PCSK9 in African Americans and Caucasians in Relation to Lp(a) Level, Apo(a) Size and Heritability. Journal of the Endocrine Society, 2020, 4, bvaa073.	0.1	6
9	The Type and Amount of Dietary Fat Affect Plasma Factor VIIc, Fibrinogen, and PAI-1 in Healthy Individuals and Individuals at High Cardiovascular Disease Risk: 2 Randomized Controlled Trials. Journal of Nutrition, 2020, 150, 2089-2100.	1.3	4
10	Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3939-3985.	1.8	42
11	Heritability of apolipoprotein (a) traits in two-generational African-American and Caucasian families. Journal of Lipid Research, 2019, 60, 1603-1609.	2.0	14
12	Effects of Fructose or Glucose on Circulating ApoCIII and Triglyceride and Cholesterol Content of Lipoprotein Subfractions in Humans. Journal of Clinical Medicine, 2019, 8, 913.	1.0	16
13	Stroke prevention. Neurology, 2019, 93, 987-988.	1.5	0
14	Statins and Lp(a): The plot thickens. Atherosclerosis, 2019, 289, 173-175.	0.4	4
15	Molecular Nutrition Fats. , 2019, , 177-187.		0
16	Reply: Is single ovary a detrimental factor for live-birth rate in IVF? Understanding the real clinical effect of unilateral oophorectomy. Human Reproduction, 2018, 33, 540-541.	0.4	1
17	Effect of antiretroviral therapy on allele-associated Lp(a) level in women with HIV in the Women's Interagency HIV Study. Journal of Lipid Research, 2018, 59, 1967-1976.	2.0	9
18	Non-HDL-C levels and residual cardiovascular risk: Do population-specific precision approaches offer any advantages?. Atherosclerosis, 2018, 274, 230-231.	0.4	13

#	Article	IF	Citations
19	Lipoprotein(a) and HIV. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 997-1004.	1.1	9
20	The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab. Journal of Lipid Research, 2017, 58, 2008-2016.	2.0	26
21	Lipoprotein(a) and apolipoprotein(a) in polycystic ovary syndrome. Clinical Endocrinology, 2016, 84, 229-235.	1.2	4
22	Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a). Metabolism: Clinical and Experimental, 2016, 65, 381-390.	1.5	37
23	Lipid Lowering with Soluble Dietary Fiber. Current Atherosclerosis Reports, 2016, 18, 75.	2.0	107
24	Lipoprotein (a): impact by ethnicity and environmental and medical conditions. Journal of Lipid Research, 2016, 57, 1111-1125.	2.0	163
25	The unresolved mystery of high-density lipoprotein: time for a paradigm shift?. Translational Research, 2016, 173, 1-6.	2.2	2
26	Mediterranean diet and cardiovascular disease: aÂstep closer to mechanisms using a precision animal model?. Translational Research, 2015, 166, 41-43.	2.2	0
27	Diverging trajectory patterns of systemic versus vascular inflammation over age in healthy Caucasians and African-Americans. Atherosclerosis, 2015, 239, 509-515.	0.4	7
28	Lipoprotein(a). Contemporary Endocrinology, 2015, , 25-55.	0.3	2
29	Rhesus monkey (Macaca mulatta) lipoprotein(a) and apolipoprotein(a): high frequency of small size apolipoprotein(a) isoforms. Journal of Medical Primatology, 2015, 44, 117-124.	0.3	6
30	Combined High-Density Lipoprotein Proteomic and Glycomic Profiles in Patients at Risk for Coronary Artery Disease. Journal of Proteome Research, 2015, 14, 5109-5118.	1.8	32
31	Attenuated Age-Impact on Systemic Inflammatory Markers in the Presence of a Metabolic Burden. PLoS ONE, 2015, 10, e0121947.	1.1	5
32	Obesity and Lifespan Healthâ€"Importance of the Fetal Environment. Nutrients, 2014, 6, 1725-1736.	1.7	30
33	Sustained Effects of a Nurse Coaching Intervention via Telehealth to Improve Health Behavior Change in Diabetes. Telemedicine Journal and E-Health, 2014, 20, 828-834.	1.6	75
34	Significant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in Africanâ€"Americans. Atherosclerosis, 2014, 235, 223-229.	0.4	19
35	Treatment options for hypertriglyceridemia: From risk reduction to pancreatitis. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 423-437.	2.2	38
36	Effects of sugarâ€sweetened beverages on plasma acylation stimulating protein, leptin and adiponectin: Relationships with Metabolic Outcomes. Obesity, 2013, 21, 2471-2480.	1.5	32

#	Article	IF	Citations
37	Risk factors for cardiovascular disease: renewed interest in triglycerides. Clinical Lipidology, 2013, 8, 1-4.	0.4	22
38	HIV Disease Activity as a Modulator of Lipoprotein(a) and Allele-Specific Apolipoprotein(a) Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 387-392.	1.1	25
39	The US Initiative: Clinical and Translational Science Awards Â– The UC Davis Perspective. Translational Research in Biomedicine, 2012, , 18-28.	0.4	0
40	Apo E4 and lipoprotein-associated phospholipase A2 synergistically increase cardiovascular risk. Atherosclerosis, 2012, 223, 230-234.	0.4	27
41	Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2969-2989.	1.8	641
42	Consumption of fructose- but not glucose-sweetened beverages for 10 weeks increases circulating concentrations of uric acid, retinol binding protein-4, and gamma-glutamyl transferase activity in overweight/obese humans. Nutrition and Metabolism, 2012, 9, 68.	1.3	117
43	The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis. BMC Endocrine Disorders, 2012, 12, 2.	0.9	69
44	Lipoprotein(a): Genotypeâ€“Phenotype Relationship and Impact on Atherogenic Risk. Metabolic Syndrome and Related Disorders, 2011, 9, 411-418.	0.5	35
45	Differential associations of serum amyloid A and pentraxin-3 with allele-specific lipoprotein(a) levels in African Americans and Caucasians. Translational Research, 2011, 158, 92-98.	2.2	11
46	Circulating Concentrations of Monocyte Chemoattractant Protein-1, Plasminogen Activator Inhibitor-1, and Soluble Leukocyte Adhesion Molecule-1 in Overweight/Obese Men and Women Consuming Fructose- or Glucose-Sweetened Beverages for 10 Weeks. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E2034-E2038.	1.8	59
47	Age as a Modulator of Inflammatory Cardiovascular Risk Factors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2151-2156.	1.1	26
48	Metabolic responses to prolonged consumption of glucose- and fructose-sweetened beverages are not associated with postprandial or 24-h glucose and insulin excursions. American Journal of Clinical Nutrition, 2011, 94, 112-119.	2.2	72
49	A Lowâ€Fat Dairy Product Enriched with Plant Sterols Improves LDL Cholesterol in Both Normal and Overweight Moderately Hypercholesterolemic Subjects. FASEB Journal, 2011, 25, .	0.2	0
50	Reengineering the National Clinical and Translational Research Enterprise: The Strategic Plan of the National Clinical and Translational Science Awards Consortium. Academic Medicine, 2010, 85, 463-469.	0.8	65
51	Linking Scientific Discovery and Better Health for the Nation: The First Three Years of the NIHÊ¼s Clinical and Translational Science Awards. Academic Medicine, 2010, 85, 457-462.	0.8	52
52	HIV protease inhibitors and obesity. Current Opinion in Endocrinology, Diabetes and Obesity, 2010, 17, 478-485.	1.2	43
53	Postprandial Lipoproteins and Cardiovascular Disease Risk in Diabetes Mellitus. Current Diabetes Reports, 2010, 10, 61-69.	1.7	29
54	Usefulness of Apolipoprotein B/Apolipoprotein A-I Ratio to Predict Coronary Artery Disease Independent of the Metabolic Syndrome in African Americans. American Journal of Cardiology, 2010, 106, 1264-1269.	0.7	22

#	Article	IF	Citations
55	Postprandial Metabolic Responses to Dietary Glycemic Index in Hypercholesterolemic Postmenopausal Women. Preventive Cardiology, 2010, 13, 29-35.	1.1	6
56	Enigmatic Role of Lipoprotein(a) in Cardiovascular Disease. Clinical and Translational Science, 2010, 3, 327-332.	1.5	13
57	Translational nutrition research at UC Davisâ€"the key role of the Clinical and Translational Science Center. Annals of the New York Academy of Sciences, 2010, 1190, 179-183.	1.8	3
58	Increased Stroke Risk and Lipoprotein(a) in a Multiethnic Community: The Northern Manhattan Stroke Study. Cerebrovascular Diseases, 2010, 30, 237-243.	0.8	27
59	Integrated Role of Two Apoliprotein E Polymorphisms on Apolipoprotein B Levels and Coronary Artery Disease in a Biethnic Population. Metabolic Syndrome and Related Disorders, 2010, 8, 531-538.	0.5	6
60	Association of Lipoprotein-Associated Phospholipase A2 with Coronary Artery Disease in African-Americans and Caucasians. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2376-2383.	1.8	25
61	Association of Lp-PLA2 activity with allele-specific Lp(a) levels in a bi-ethnic population. Atherosclerosis, 2010, 211, 526-530.	0.4	17
62	Relationship of Postprandial Nonesterified Fatty Acids, Adipokines, and Insulin Across Gender in Human Immunodeficiency Virusâ€"Positive Patients Undergoing Highly Active Antiretroviral Therapy. Metabolic Syndrome and Related Disorders, 2009, 7, 199-204.	0.5	0
63	Human Immunodeficiency Virus and Highly Active Antiretroviral Therapyâ€"Associated Metabolic Disorders and Risk Factors for Cardiovascular Disease. Metabolic Syndrome and Related Disorders, 2009, 7, 401-409.	0.5	53
64	Measures of postprandial lipoproteins are not associated with coronary artery disease in patients with type 2 diabetes mellitus. Journal of Lipid Research, 2009, 50, 1901-1909.	2.0	18
65	ApoE and ApoC-I polymorphisms: association of genotype with cardiovascular disease phenotype in African Americans. Journal of Lipid Research, 2009, 50, 1472-1478.	2.0	11
66	UC Davis CTSA: Coming of Age. Clinical and Translational Science, 2009, 2, 98-101.	1.5	3
67	Comparison of C-Reactive Protein and Metabolic Syndrome as Cardiovascular Risk Factors in African-Americans and European-Americans. American Journal of Cardiology, 2009, 103, 523-527.	0.7	10
68	Cardiovascular Disease in Womenâ€"Challenges Deserving a Comprehensive Translational Approach. Journal of Cardiovascular Translational Research, 2009, 2, 251-255.	1.1	2
69	Synergistic role of inflammation and insulin resistance as coronary artery disease risk factors in African Americans and Caucasians. Atherosclerosis, 2009, 205, 290-295.	0.4	20
70	Strategies for Innovation and Interdisciplinary Translational Research. Journal of Investigative Medicine, 2009, 57, 474-476.	0.7	15
71	Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. Journal of Clinical Investigation, 2009, 119, 1322-1334.	3.9	1,394
72	Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease. Clinica Chimica Acta, 2008, 394, 59-62.	0.5	47

#	Article	IF	Citations
73	Increased lipoprotein remnant cholesterol levels in HIV-positive patients during antiretroviral therapy. Atherosclerosis, 2008, 198, 192-197.	0.4	14
74	The apolipoprotein(a) gene: Linkage disequilibria at three loci differs in African Americans and Caucasians. Atherosclerosis, 2008, 201, 138-147.	0.4	13
75	High Levels of Inflammatory Biomarkers Are Associated with Increased Allele-Specific Apolipoprotein(a) Levels in African-Americans. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1482-1488.	1.8	32
76	ApoE genotype affects allele-specific apo[a] levels for large apo[a] sizes in African Americans: the Harlem-Basset Study. Journal of Lipid Research, 2007, 48, 693-698.	2.0	17
77	Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states. American Journal of Clinical Nutrition, 2007, 86, 1611-1620.	2.2	121
78	HIV and Highly Active Antiretroviral Therapy: Dyslipidemia, Metabolic Aberrations, and Cardiovascular Risk. Preventive Cardiology, 2007, 10, 96-103.	1.1	10
79	Adiponectin levels are associated with coronary artery disease across Caucasian and African-American ethnicity. Translational Research, 2007, 149, 317-323.	2.2	22
80	Metabolic Syndrome Components in African-Americans and European-American Patients and Its Relation to Coronary Artery Disease. American Journal of Cardiology, 2007, 100, 830-834.	0.7	27
81	Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states. American Journal of Clinical Nutrition, 2007, 86, 1611-1620.	2.2	73
82	Lipoprotein(a): A Unique Risk Factor for Cardiovascular Disease. Clinics in Laboratory Medicine, 2006, 26, 751-772.	0.7	86
83	Textbook on Nutrition and AIDS. American Journal of Clinical Nutrition, 2006, 84, 1556.	2.2	0
84	Lipoprotein(a) and Thrombocytes: Potential Mechanisms Underlying Cardiovascular Risk. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2006, 35, 314-321.	0.5	10
85	Lipoprotein Metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1201-1203.	1.1	5
86	Apo[a] size and PNR explain African American-Caucasian differences in allele-specific apo[a] levels for small but not large apo[a]. Journal of Lipid Research, 2006, 47, 982-989.	2.0	23
87	Heparins Increase Endothelial Nitric Oxide Bioavailability by Liberating Vessel-Immobilized Myeloperoxidase. Circulation, 2006, 113, 1871-1878.	1.6	172
88	Protective effect of apolipoprotein E2 on coronary artery disease in African Americans is mediated through lipoprotein cholesterol. Journal of Lipid Research, 2006, 47, 2475-2481.	2.0	32
89	Postprandial response to a physiologic caloric load in HIV-positive patients receiving protease inhibitorâ€“based or nonnucleoside reverse transcriptase inhibitorâ€“based antiretroviral therapy. American Journal of Clinical Nutrition, 2005, 82, 146-154.	2.2	3
90	Postprandial response to a physiologic caloric load in HIV-positive patients receiving protease inhibitorâ€“based or nonnucleoside reverse transcriptase inhibitorâ€“based antiretroviral therapy. American Journal of Clinical Nutrition, 2005, 82, 146-154.	2.2	4

#	Article	IF	Citations
91	Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia. Journal of Lipid Research, 2005, 46, 2735-2744.	2.0	34
92	The common insertional polymorphism in the APOC1 promoter is associated with serum apolipoprotein C-I levels in Hispanic children. Atherosclerosis, 2005, 179, 387-393.	0.4	13
93	Nutrition and Heart Disease: Causation and Prevention. American Journal of Clinical Nutrition, 2004, 80, 1672.	2.2	0
94	Growth Hormone Induces Low-Density Lipoprotein Clearance but not Bile Acid Synthesis in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 349-356.	1.1	40
95	Lipoprotein(a). Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 2219-2226.	1.1	206
96	High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort. Journal of the American College of Cardiology, 2004, 43, 1828-1833.	1.2	60
97	Postprandial lipemia and cardiovascular disease. Current Atherosclerosis Reports, 2003, 5, 437-444.	2.0	141
98	Physical Fitness and C-Reactive Protein Level in Children and Young Adults: The Columbia University BioMarkers Study. Pediatrics, 2003, 111, 332-338.	1.0	104
99	Cholesterol Absorption and the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1314-1316.	1.1	10
100	Therapy and clinical trials. Current Opinion in Lipidology, 2003, 14, 227-230.	1.2	0
101	Apolipoprotein E and diets: a case of gene-nutrient interaction?. Current Opinion in Lipidology, 2002, 13, 25-32.	1.2	37
102	Apolipoproteins and carotid artery atherosclerosis in an elderly multiethnic population: the Northern Manhattan stroke study. Atherosclerosis, 2002, 165, 317-325.	0.4	23
103	Relation of Apo(a) Size to Carotid Atherosclerosis in an Elderly Multiethnic Population. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 141-146.	1.1	54
104	Lipoprotein (a): Where does the atherogenicity reside?. Translational Research, 2002, 139, 131-132.	2.4	5
105	Comparison of modifiable determinants of lipids and lipoprotein levels among African-Americans, Hispanics, and Non-Hispanic Caucasians â‰¥65 years of age living in New York City. American Journal of Cardiology, 2002, 89, 178-183.	0.7	41
106	Apolipoprotein [a] genotype influences isoform dominance pattern differently in African Americans and Caucasians. Journal of Lipid Research, 2002, 43, 234-244.	2.0	39
107	Apolipoprotein [a] genotype influences isoform dominance pattern differently in African Americans and Caucasians. Journal of Lipid Research, 2002, 43, 234-44.	2.0	34
108	On the anti-atherogenic effect of the antioxidant BHT in cholesterol-fed rabbits: inverse relation between serum triglycerides and atheromatous lesions. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2001, 1534, 129-138.	1.2	12

#	Article	IF	Citations
109	Retinol binding protein as a surrogate measure for serum retinol: studies in vitamin Aâ€“deficient children from the Republic of the Marshall Islands. American Journal of Clinical Nutrition, 2001, 73, 594-601.	2.2	82
110	The APOE gene and dietsâ€”food (and drink) for thought. American Journal of Clinical Nutrition, 2001, 73, 669-670.	2.2	14
111	Fluorescence-based, Nonradioactive Method for Efficient Detection of the Pentanucleotide Repeat (TTTTA)n Polymorphism in the Apolipoprotein(a) Gene. Clinical Chemistry, 2001, 47, 1758-1762.	1.5	5
112	High-Density Lipoprotein Cholesterol and Ischemic Stroke in the Elderly. JAMA - Journal of the American Medical Association, 2001, 285, 2729.	3.8	265
113	Predictors of postprandial triacylglycerol response in children: the Columbia University Biomarkers Study. American Journal of Clinical Nutrition, 2000, 72, 1119-1127.	2.2	29
114	Normal Ovulatory Women with Polycystic Ovaries Have Hyperandrogenic Pituitary-Ovarian Responses To Gonadotropin-Releasing Hormone-Agonist Testing*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 995-1000.	1.8	82
115	High Levels of Lp(a) With a Small Apo(a) Isoform Are Associated With Coronary Artery Disease in African American and White Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2619-2624.	1.1	154
116	Plasma Sphingomyelin Level as a Risk Factor for Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2614-2618.	1.1	343
117	Hand-grip muscle strength, lean body mass, and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. American Journal of Kidney Diseases, 2000, 36, 1213-1225.	2.1	241
118	Relations of Plasma Fibrinogen Level in Children to Measures of Obesity, the (G-455ÂA) Mutation in the Â-Fibrinogen Promoter Gene, and Family History of Ischemic Heart Disease: The Columbia University BloMarkers Study. American Journal of Epidemiology, 1999, 150, 737-746.	1.6	24
119	Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney International, 1999, 55, 1899-1911.	2.6	1,498
120	Family history of early cardiovascular disease in children with moderate to severe hypercholesterolemia: Relationship to lipoprotein (a) and low-density lipoprotein cholesterol levels. Translational Research, 1999, 133, 237-244.	2.4	11
121	Effect of long-term beta-carotene and vitamin A on serum cholesterol and triglyceride levels among participants in the Carotene and Retinol Efficacy Trial (CARET). Atherosclerosis, 1999, 143, 427-434.	0.4	27
122	Erratum to â€œEffect of long-term beta-carotene and vitamin A on serum cholesterol and triglyceride levels among participants in the Carotene and Retinol Efficacy trial (CARET)â€• Atherosclerosis, 1999, 145, 423.	0.4	5
123	Heme Oxygenase Inhibitors Transiently Increase Serum Ferritin Concentrations without Altering Other Acute-Phase Reactants in Man. Pharmacology, 1999, 59, 51-56.	0.9	13
124	A common Hpa I RFLP of apolipoprotein C-I increases gene transcription and exhibits an ethnically distinct pattern of linkage disequilibrium with the alleles of apolipoprotein E. Journal of Lipid Research, 1999, 40, 50-58.	2.0	61
125	Hepatic cholesterol metabolism in experimental nephrotic syndrome. Lipids, 1998, 33, 165-169.	0.7	9
126	Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney International, 1998, 53, 1336-1342.	2.6	69

#	Article	IF	Citations
127	Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach. Journal of Lipid Research, 1998, 39, 913-924.	2.0	35
128	Safety and efficacy of Omacor in severe hypertriglyceridemia. European Journal of Cardiovascular Prevention and Rehabilitation, 1997, 4, 385-391.	1.5	279
129	Cardiovascular prognosis in relation to apolipoproteins and other lipid parameters in patients with stable angina pectoris treated with verapamil or metoprolol. Atherosclerosis, 1997, 135, 109-118.	0.4	16
130	Hormonal Regulation of Lipoprotein(a) Levels: Effects of Estrogen Replacement Therapy on Lipoprotein(a) and Acute Phase Reactants in Postmenopausal Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1822-1829.	1.1	75
131	On the interrelationship between hepatic carnitine, fatty acid oxidation, and triglyceride biosynthesis in nephrosis. Lipids, 1997, 32, 847-852.	0.7	4
132	Antibodies Against Cardiolipin and Oxidatively Modified LDL in 50-Year-Old Men Predict Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 3159-3163.	1.1	181
133	Association of Apo E Polymorphism With Plasma Lipid Levels in a Multiethnic Elderly Population. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 3534-3541.	1.1	87
134	Race-Ethnicity and Determinants of Carotid Atherosclerosis in a Multiethnic Population. Stroke, 1997, 28, 929-935.	1.0	130
135	Influence of a diet regimen on glucose homeostasis and serum lipid levels in male elite athletes. Metabolism: Clinical and Experimental, 1996, 45, 435-441.	1.5	5
136	Increased Plasma Lipoprotein(a) in Continuous Ambulatory Peritoneal Dialysis Is Related to Peritoneal Transport of Proteins and Glucose. Nephron, 1996, 72, 135-144.	0.9	56
137	Diet and drug therapy for lipoprotein (a). Current Opinion in Lipidology, 1995, 6, 48-56.	1.2	49
138	Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: Reduced activity of cholesterol 7Î±-hydroxylase. Hepatology, 1995, 21, 1025-1030.	3.6	62
139	Hepatic Fatty Acid Metabolism as a Determinant of Plasma and Liver Triacylglycerol Levels. FEBS Journal, 1995, 227, 715-722.	0.2	0
140	Hormonal Regulation of Serum Lipoprotein(a) Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 847-849.	1.1	46
141	Studies on rat liver phosphatidate phosphohydrolase and plasma lipids: Effect of HMG-CoA reductase inhibitors. Lipids and Lipid Metabolism, 1994, 1214, 32-38.	2.6	9
142	Lack of association between apolipoprotein E allele É›4 and sporadic Alzheimer's disease. Neuroscience Letters, 1994, 169, 175-178.	1.0	56
143	Lipoprotein(a) in nephrotic syndrome. Kidney International, 1993, 44, 1116-1123.	2.6	57
144	Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. American Journal of Medicine, 1993, 94, 13-20.	0.6	169

#	Article	IF	Citations
145	Effect of nâˆ’3 fatty acids on the key enzymes involved in cholesterol and triglyceride turnover in rat liver. Lipids, 1991, 26, 385-389.	0.7	53
146	Influence of Pravastatin, a Specific Inhibitor of HMG-CoA Reductase, on Hepatic Metabolism of Cholesterol. New England Journal of Medicine, 1990, 323, 224-228.	13.9	267
147	TIN-PROTOPORPHYRIN AND LONG WAVE LENGTH ULTRAVIOLET LIGHT IN TREATMENT OF PSORIASIS. Lancet, The, 1989, 333, 1231-1233.	6.3	36
148	Activation of rat liver cytosolic phosphatidic acid phosphatase by nucleoside diphosphates. Lipids and Lipid Metabolism, 1989, 1002, 382-387.	2.6	7
149	HYPOCHOLESTEROLAEMIA AND INCREASED ELIMINATION OF LOW-DENSITY LIPOPROTEINS IN METASTATIC CANCER OF THE PROSTATE. Lancet, The, 1989, 334, 1178-1180.	6.3	70
150	Sn-protoporphyrin lowers serum bilirubin levels, decreases biliary bilirubin output, enhances biliary heme excretion and potently inhibits hepatic heme oxygenase activity in normal human subjects. Hepatology, 1988, 8, 625-631.	3.6	45
151	Stimulatory effect of mevinolin on rat liver phosphatidic acid phosphatase. Lipids and Lipid Metabolism, 1987, 920, 20-25.	2.6	10
152	Plasma Exchange in a Patient with Heterozygous Familial Hypercholesterolaemia Resistant to Drug Therapy. Acta Medica Scandinavica, 1987, 221, 317-320.	0.0	6
153	Kinetic properties of pig pyruvate kinases type A from kidney and type M from muscle. Archives of Biochemistry and Biophysics, 1979, 195, 347-361.	1.4	23
154	Phosphorylation of rat kidney pyruvate kinase type L by cyclic 3â€²,5â€²-amp-dependent protein kinase. Biochimica Et Biophysica Acta - Biomembranes, 1978, 524, 68-77.	1.4	3
155	The minimum substrate of cyclic AMP-stimulated protein kinase, as studied by synthetic peptides representing the phosphorylatable site of pyruvate kinase (type L) of rat liver. Biochemical and Biophysical Research Communications, 1976, 70, 696-703.	1.0	209
156	Studies on the Kinetic Effects of Adenosine-3': 5'-MonophosphateDependent Phosphorylation of Purified Pig-Liver Pyruvate Kinase Type L. FEBS Journal, 1976, 68, 497-506.	0.2	57
157	Non-dependence on native structure of pig liver pyruvate kinase when used as a substrate for cyclic 3â€²,5â€²-AMP-stimulated protein kinase. Biochemical and Biophysical Research Communications, 1975, 66, 614-621.	1.0	61
158	Regulatory Phosphorylation of Purified Pig Liver Pyruvate Kinase. , 1974, , 192-204.		1
159	Cyclic 3â€²,5â€²-AMP-Stimulated and Non-stimulated Phosphorylation of Protein Fractions from Rat-liver Cell Sap on Incubation with (Î³-32P)ATP. Upsala Journal of Medical Sciences, 1974, 79, 129-137.	0.4	14
160	Clinical and Translational Science and Climate Change â€“ Time for Action. Journal of Clinical and Translational Science, 0, , 1-5.	0.3	2